Literature DB >> 24914380

Prognostic factors in stage IB gastric cancer.

Toru Aoyama1, Takaki Yoshikawa1, Hirohito Fujikawa1, Tsutomu Hayashi1, Takashi Ogata1, Haruhiko Cho1, Takanobu Yamada1, Shinichi Hasegawa1, Kazuhito Tsuchida1, Norio Yukawa1, Takashi Oshima1, Mari S Oba1, Satoshi Morita1, Yasushi Rino1, Munetaka Masuda1.   

Abstract

AIM: To identify the subset of patients with stage IB gastric cancer with an unfavorable prognosis.
METHODS: Overall survival (OS) rates were examined in 103 patients with stage IB (T1N1M0 and T2N0M0) gastric cancer between January 2000 and December 2011. Univariate and multivariate analyses were performed to identify risk factors using a Cox proportional hazards model.
RESULTS: The OS rates of patients with T1N1 and T2N0 cancer were 89.2% and 94.1% at 5-years, respectively. Both univariate and multivariate analyses demonstrated that tumor location was the only significant prognostic factor. The OS rate was 81.8% at 5-years when the tumor was located in the upper third of the stomach and was 95.5% at 5-years when the tumor was located in the middle or lower third of the stomach (P = 0.0093).
CONCLUSION: These data may suggest that tumor location is associated with survival in patients with stage IB gastric cancer.

Entities:  

Keywords:  Gastric cancer; Prognostic factor; Stage IB

Mesh:

Year:  2014        PMID: 24914380      PMCID: PMC4047344          DOI: 10.3748/wjg.v20.i21.6580

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.

Authors:  Toru Aoyama; Takaki Yoshikawa; Tsutomu Hayashi; Hiroshi Kuwabara; Yo Mikayama; Takashi Ogata; Haruhiko Cho; Akira Tsuburaya
Journal:  Ann Surg Oncol       Date:  2011-12-06       Impact factor: 5.344

Review 2.  Disparities in gastric cancer chemotherapy between the East and West.

Authors:  Atsushi Ohtsu; Shigeaki Yoshida; Nagahiro Saijo
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

3.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

4.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

5.  Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.

Authors:  Toru Aoyama; Takaki Yoshikawa; Takafumi Watanabe; Tsutomu Hayashi; Takashi Ogata; Haruhiko Cho; Akira Tsuburaya
Journal:  Gastric Cancer       Date:  2011-04-02       Impact factor: 7.370

6.  Proximal versus distal gastric carcinoma--what are the differences?

Authors:  P Piso; U Werner; H Lang; P Mirena; J Klempnauer
Journal:  Ann Surg Oncol       Date:  2000-08       Impact factor: 5.344

7.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

8.  Recurrence in early gastric cancer with lymph node metastasis.

Authors:  Makoto Saka; Hitoshi Katai; Takeo Fukagawa; Rajwinder Nijjar; Takeshi Sano
Journal:  Gastric Cancer       Date:  2009-01-08       Impact factor: 7.370

9.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Authors:  Narikazu Boku; Seiichiro Yamamoto; Haruhiko Fukuda; Kuniaki Shirao; Toshihiko Doi; Akira Sawaki; Wasaburo Koizumi; Hiroshi Saito; Kensei Yamaguchi; Hiroya Takiuchi; Junichiro Nasu; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2009-10-07       Impact factor: 41.316

10.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

View more
  11 in total

Review 1.  Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?

Authors:  Linda Agolli; Riccardo Maurizi Enrici; Mattia Falchetto Osti
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

2.  Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis.

Authors:  Y Wang; J Zhang; S Guo; Z Dong; X Meng; G Zheng; D Yang; Z Zheng; Y Zhao
Journal:  Clin Transl Oncol       Date:  2019-03-22       Impact factor: 3.405

3.  Potential benefits of laparoscopy-assisted proximal gastrectomy with esophagogastrostomy for cT1 upper-third gastric cancer.

Authors:  Kei Hosoda; Keishi Yamashita; Natsuya Katada; Hiromitsu Moriya; Hiroaki Mieno; Tomotaka Shibata; Shinichi Sakuramoto; Shiro Kikuchi; Masahiko Watanabe
Journal:  Surg Endosc       Date:  2015-10-28       Impact factor: 4.584

4.  Prognostic Factors in Stage IB Gastric Cancer after Surgical Resection.

Authors:  Byunghyuk Yu; Ji Yeon Park; Ki Bum Park; Oh Kyoung Kwon; Seung Soo Lee; Ho Young Chung
Journal:  J Gastric Cancer       Date:  2020-09-23       Impact factor: 3.720

Review 5.  Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer.

Authors:  Ke-Kang Sun; Qing-Hua Wang; Yong-You Wu
Journal:  Oncol Lett       Date:  2020-08-19       Impact factor: 2.967

6.  Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience.

Authors:  Peng Jin; Xiaoyan Ji; Shuai Ma; Wenzhe Kang; Hao Liu; Yang Li; Fuhai Ma; Haitao Hu; Weikun Li; Yantao Tian
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-09       Impact factor: 4.553

7.  FLAD1 is up-regulated in Gastric Cancer and is a potential prediction of prognosis.

Authors:  Pan Hu; Yuhang Pan; Chenyang Wang; Wenhui Zhang; He Huang; Jiani Wang; Nana Zhang
Journal:  Int J Med Sci       Date:  2020-07-06       Impact factor: 3.738

8.  Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method.

Authors:  Victor Hugo Fonseca de Jesus; Wilson Luiz da Costa; Tiago Cordeiro Felismino; Vinicius Fernando Calsavara; Alessandro Landskron Diniz; Heber Salvador de Castro Ribeiro; André Luis de Godoy; Igor Correia de Farias; Felipe José Fernandez Coimbra
Journal:  J Gastrointest Oncol       Date:  2019-12

9.  Downregulation of FOXK2 is associated with poor prognosis in patients with gastric cancer.

Authors:  Xi Liu; Xiaodong Wei; Wei Niu; Dong Wang; Bo Wang; Hao Zhuang
Journal:  Mol Med Rep       Date:  2018-09-07       Impact factor: 2.952

10.  Extensive small bowel metastasis and peritoneal dissemination 1 year following curative gastrectomy for T1N1 gastric cancer: A case report.

Authors:  Shengxian Fan; Min Feng; Meng Wang; Wenxian Guan
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.